Inhibrx Biosciences, Inc. (NasdaqGS: INBX)
Health Care · Biotechnology · US
$125.34
+2.13% today · +383.7% 1Y
Inhibrx Biosciences, Inc. (NasdaqGS: INBX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.84B and employs 110 people.
Over the last twelve months the share price has gained 383.7%, trading between 24.27 and 155.29.
Tweenvest scores Inhibrx Biosciences, Inc. across four factors: quality 10/100. Its strongest factor is quality.
INBX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.84B
- Revenue (TTM)
- $0.00
- P/E
- —
- EPS
- -8.88
- Dividend yield
- —
- Beta (5Y)
- 3.52
- 52-week high
- $155.29
- 52-week low
- $24.27
- Avg volume (3M)
- —
- Shares outstanding
- 14.72M
- Employees
- 110
- Next earnings
- —
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
- ISIN
- US45720N1037
- Founded
- 2024
- Listed since
- May 29, 2024
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.